Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

A Year of Growth and Collaboration: IPC’s 2024 International Fellows

IPC's 2024 International Fellows

The 2024 IPC International Fellows have spent the past year immersed in global dermatology through their work with IPC. From engaging in virtual meetings to connecting with leading psoriasis experts and mentors, their experiences have been diverse and educational. In this blog post, hear directly from all eight 2024 Fellows as they share their reflections and experiences through recordings from the 2024 IPC Think Tank Meeting in London. Join us in celebrating these dedicated dermatologists as they reflect on a transformative year of learning, growth, and global collaboration.

María Julia Cura, MD

Hospital Italiano de Buenos Aires

Buenos Aires, Argentina

IPC Jr. Councilor

Bio

Dr. María Julia Cura, a clinical researcher and co-leader of the psoriasis team at Hospital Italiano in Buenos Aires, Argentina, was mentored by IPC Councilor Diamant Thaçi at the University of Lübeck in Germany. She also attended and participated in the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, where her digital poster, A Digital Tool Connecting Patients with the HealthCare System Through Psoriasis Virtual Community, was shared and displayed.

Ashar Vijay Dhana, MBBCh, MPH, MMED, FC Derm, SCE-Dermatology, PhD

Groote Schuur Academic Hospital

Cape Town, South Africa

IPC Jr. Councilor

Bio

Dr. Ashar Vijay Dhana is a consultant dermatologist in the Division of Dermatology at Groote Schuur Academic Hospital in Cape Town, South Africa. He was mentored by IPC Councilor Andrew Pink at the St. John’s Institute of Dermatology in London, United Kingdom. He attended the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California. Dr. Dhana’s future goals include establishing a dedicated psoriasis care program at his institution and advancing clinical research in prediction models and individual participant data meta-analysis.

Bryan Guevara, MD, FPDS, FPDSP-PDS, ICDP-UEMS

Southeast Dermatology Specialists

Davao City & Iloilo City, Philippines

IPC Jr. Councilor

Bio

Dr. Bryan Ko Guevara is a board-certified dermatologist and dermatopathologist at the Southern Philippines Medical Center and Southeast Dermatology. During his onsite visit to Manchester, United Kingdom, he was mentored by IPC Founder Christopher Griffiths and IPC Councilor Darren Ashcroft, collaborating closely with the Global Psoriasis Atlas (GPA) team. Dr. Guevara attended the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, earlier this year. He has also been honored with the International League of Dermatological Societies (ILDS) Young Dermatologist International Achievement Award (YDIA) for 2025.

Jan Hugo, MD, PhD

University Hospital Královské Vinohrady

Prague, Czech Republic

IPC Jr. Councilor

Bio

Dr. Jan Hugo leads the outpatient unit at the Department of Dermatovenerology at the University Hospital Královské Vinohrady in Prague, Czech Republic. In June, he attended the International Federation of Psoriasis Associations (IFPA) Conference in Stockholm, Sweden. He traveled to Ghent, Belgium, for his onsite visit with mentor IPC Councilor Jo Lambert at Ghent University Hospital in Ghent in October. Dr. Hugo is committed to fostering international collaboration within the IPC community and is currently working on publishing a multicentric analysis of biologics in elderly patients.

Shekhar Neema, MD

Base Hospital

Lucknow, India

IPC Jr. Councilor

Bio

Dr. Shekhar Neema is an Associate Professor of Dermatology at Base Hospital, affiliated with King George Medical University in Lucknow, India. In May 2024, as part of his mentorship with IPC Councilor Elise Kleyn, he participated in his onsite visit to the University of Manchester, United Kingdom, where he gained experience in their psoriasis clinic and collaborated with the Global Psoriasis Atlas (GPA) team. Dr. Neema attended the Psoriasis: From Gene to Clinic 10th International Congress this December and is committed to continuing his work in psoriasis and supporting patient groups.

Josep Riera-Monroig, MD

Hospital Clínic de Barcelona

Barcelona, Spain

IPC Jr. Councilor

Bio

Dr. Josep Riera Monroig is a consultant dermatologist at the Hospital Clínic de Barcelona in Spain and a lecturer at the Faculty of Medicine, University of Barcelona. He traveled to the University of California, San Francisco, for mentorship with IPC Councilor Wilson Liao, where he gained experience in the psoriasis clinic and the research lab and attended the 2024 AAD Meeting in March. Dr. Riera Monroig aims to build and strengthen partnerships across institutions while advancing expertise in advanced methodologies and technologies.

Huidi Shucheng, MD, PhD, MPH

West China Hospital, Sichuan University

Chengdu, China

Bio

Dr. Huidi Shucheng is an attending dermatologist in the Department of Dermatology and Venereology at West China Hospital, Sichuan University. He received mentorship from IPC Board Member Joel Gelfand at the University of Pennsylvania in Philadelphia, Pennsylvania. During this time, he attended the Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas. Dr. Shucheng’s future goals include advancing psoriasis care by exploring risk factors, biomarkers, and novel therapeutics to improve treatment outcomes and contributing to personalized, evidence-based treatment strategies to enhance patient outcomes.

Alison Treichel, MD

University of Rochester

Rochester, New York, United States

IPC Jr. Councilor

Bio

Dr. Alison Treichel is a PGY-4 dermatology resident at University Hospitals Cleveland Medical Center under the mentorship of IPC Councilor Dr. Kevin Cooper. Her IPC Fellowship Mentor was IPC Councilor and Fellowship Program Alumni Álvaro González-Cantero, with whom she studied at Hospital Ramón y Cajal in Madrid, Spain. Dr. Treichel also attended the 53rd Annual European Society for Dermatological Research (ESDR) Meeting in Lisbon in September and presented research on circulating monocytes in psoriasis patients treated with apremilast at the Psoriasis: From Gene to Clinic 10th International Congress. She hopes to continue her work in academic practice and clinical/translational research.

The IPC and our 2024 Fellows are grateful to this year’s International Fellowship Program Sponsor, Bristol Myers Squibb (BMS). Thanks to their generous support, our Fellows have engaged in impactful experiences, from collaborating with global psoriasis experts to advancing their research and clinical skills. This partnership has been instrumental in shaping the next generation of leaders in psoriasis care.

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026